|Day's Range||248.88 - 251.79|
|52 Week Range||184.50 - 261.27|
|PE Ratio (TTM)||7.82|
|Dividend & Yield||2.80 (1.14%)|
|1y Target Est||N/A|
Shares of Valeant Pharmaceuticals International (VRX) are climbing Monday after the drug maker announced the $190 million sale of Obagi Medical Products to Shonghua Finance Acquisition Fund. The deal is the latest asset sale by the beleaguered drug maker as it labors to meet its goal of $5 billion in debt reduction by February 2018. The company has shed its iNova division, as well as cancer treatment maker Dendreon, and sold some skin care lines to L’Oreal, and is throwing the proceeds at its debt load.
Allergan's International segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.
The US General Medicines segment reported revenues of $1.35 billion in 1Q17, which marked a 7.4% decline from its $1.45 billion in 1Q16.